secwatch.observer — SEC 8-K summary
======================================

Issuer:     EAGLE PHARMACEUTICALS, INC. (—)
CIK:        0000827871
Form:       8-K
Filed at:   2024-11-27T23:59:59+00:00
Accession:  0001104659-24-123472
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eagle Pharmaceuticals dismisses EY, appoints BDO as auditor amid restatement
----------------------------------------------------------------------------

- EY dismissed on Nov 21, 2024; BDO engaged on Nov 26, 2024 for FY2022, FY2023, and FY2024 audits.
- Restatement covers FY2022, Q2-Q3 2022, Q1-Q2 2023; later periods delayed due to material weaknesses.
- Material weaknesses in internal control over financial reporting identified, requiring expanded audit procedures.
- No disagreements with EY except for restatement and material weaknesses; EY letter filed as Exhibit 16.1.
- Company's stock delisted from Nasdaq, now trading OTC under symbol EGRX since Oct 4, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/827871/000110465924123472/0001104659-24-123472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/827871/000110465924123472/tm2429505d10_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-123472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer